IOVA vs PEN
Iovance Biotherapeutics, Inc. vs Penumbra, Inc. — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
PEN
Penumbra, Inc.
67
Buy
| Metric | IOVA | PEN |
|---|
| AI Score |
67
|
67
|
| Price |
$6.49
|
$326.07
|
| P/E Ratio |
-9.27×
|
79.78×
|
| ROE |
-56.0%
|
12.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
67.8%
|
| Debt / Equity |
0.06×
|
0.14×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.2
|
79.6
|
| Beta |
0.701
|
0.701
|
| Expected Upside |
—
|
+6.3%
|
AI Committee View
Current Innellis committee reasoning for IOVA versus PEN.
The committee scores are tied.
IOVA and PEN both score 67/100.
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical